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Abstract
Background: Anti-citrullinated-peptide antibodies (ACPA) have been detected in individuals with developing
rheumatoid arthritis (RA) before the onset of symptom, with an initially limited spectrum of reactivities that
gradually broadens. The aim was to analyze the evolution of ACPA response pre-dating symptom onset, using four
selected citrullinated exogenous and endogenous antigens.
Methods: A cohort of 521 individuals sampled before symptoms of RA appeared and 272 population controls were
identified from the Biobank of Northern Sweden; 241 samples from patients with early RA were also collected.
ACPA were detected by ELISA on viral citrullinated peptides (VCP) derived from Epstein-Barr-virus nuclear antigen
(EBNA)1 and EBNA2 (VCP1 and VCP2) and histone-4-derived citrullinated peptides (HCP1 and HCP2).
Results: In pre-symptomatic individuals vs. patients with early RA, anti-VCP1 antibodies were detected in 10.4 % vs.
36.1 %, anti-VCP2 in 17.1 % vs. 52.3 %, anti-HCP1 in 10.2 % vs. 37.3 %, and anti-HCP2 in 16.3 % vs. 48.5 %,
respectively. Anti-VCP and anti-HCP concentrations were significantly increased in pre-symptomatic individuals
vs. controls (p < 0.001) and were increased approaching symptom onset. Anti-VCP and anti-HCP appeared
simultaneously (median (IQR) 5.3 (6) years before symptom onset) and in combination yielded a high-risk ratio for
disease development (OR = 8.0–18.9). Anti-VCP2 and anti-HCP2 antibodies were associated with HLA-DRB1*0401
in pre-symptomatic individuals. Three peptidylarginine deiminase (PAD)I3/PADI4 single nucleotide
polymorphisms (SNPs) were significantly associated with anti-HCP1.
Conclusions: Anti-VCP and anti-HCP antibodies pre-date symptom onset and predict disease development, but
no hierarchy of citrullinated epitopes can be identified. These results suggest that no inciting citrullinated
antigen so far described is common to all patients with RA. The association between PADI3/PADI4 polymorphism
and anti-HCP1 antibodies suggests a novel link between deimination and production of ACPA.
Background
Rheumatoid arthritis, a chronic inflammatory auto-
immune disease, is a complex and multifactorial disorder
influenced by both genetic and environmental factors [1].
A distinctive feature of RA is the presence of anti-
citrullinate-peptide antibodies (ACPA), i.e., autoantibodies
directed against peptides/proteins in which arginine resi-
dues have been post-translationally modified into citrulline
by peptidilarginine deiminase [2]. ACPA may recognize
numerous citrullinated antigens: filaggrin, alpha and beta
fibrin/fibrinogen, alpha-enolase, vimentin, histones, and
Epstein-Barr virus (EBV)-derived proteins [3, 4]. Because
of their strict disease specificity, ACPA have recently been
included in the American College of Rheumatologists/
European League Against Rheumatism (ACR/EULAR)
criteria for diagnosis of RA [5].
ACPA appear very early in the course of the disease,
even years before disease manifestations, with an increase
in concentrations approaching disease onset [6, 7]. During
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pre-clinical phases, ACPA recognize a limited number of
citrullinated antigens and display low affinity for their
antigenic targets [8]. Epitope spreading towards other
citrullinated epitopes and avidity maturation occur, and a
full repertoire of high-affinity ACPA is established before
the onset of the disease and is associated with the disease
course [8–10].
The events that take place during the pre-clinical stage
and finally lead to the production of high-affinity poly-
clonal ACPA are not yet elucidated. A current hypothesis
is that inflammatory/infectious stimuli induce deimination
of exogenous or endogenous antigens, leading to the ex-
pansion and differentiation of ACPA-producing B cells, an
event occurring mainly in ectopic lymphoid structures
(ELS) [11]. The trigger of infectious agents is a possible
explanation. EBV, proposed as an inducing agent in RA
on the basis of epidemiological and serological data, is an
ideal candidate and its presence in synovial ELS further
supports its possible role [11, 12]. Alternatively, B-cell dif-
ferentiation may be induced by the release of citrullinated
antigens in a molecular milieu abundant with danger sig-
nals. The recent discovery of neutrophil extracellular traps
(NETs) as a source of citrullinated antigens, and namely
citrullinated histones H3 and H4 [13, 14], intimately asso-
ciated with pro-inflammatory signals such as LL-37 [15],
may be consistent with this hypothesis. In fact, synovial
fluid neutrophils have enhanced NETosis in RA, exposing
citrullinated antigens that may fuel the production of
ACPA [16, 17]. These observations led to the hypothesis
that aberrant NETosis is a triggering event in RA, as sug-
gested for other autoimmune diseases. We have previously
described deiminated sequences contained in EBV-derived
proteins EBNA1 and EBNA2 as specific targets of ACPA,
[18, 19] and that sera from patients with RA also react
with deiminated H4 released during NETosis [14].
We took advantage to focus on these fully character-
ized ACPA targets, corresponding to exogenous antigens
(i.e., viral citrullinated peptide (VCP)1 derived from
EBNA1, VCP2 from EBNA2) or endogenous antigens
(histone citrullinated peptide (HCP)1 and HCP2 from
histone H4), to analyse a cohort of individuals without
joint symptoms who have subsequently developed RA.
The aim of the present work was to test the hypothesis
that there is a hierarchy of citrullinated epitopes between
exogenous and endogenous antigens in the build-up of
the ACPA response in patients with RA.
Methods
Study population
A nested case-control study was performed based on indi-
viduals included in population-based survey cohorts
within the Medical Biobank of Northern Sweden. The cri-
teria concerning the recruitment, blood sampling and
storage conditions (−80 C) have been described previously
[6]. The register of patients attending the Department
of Rheumatology, University Hospital of Umeå, and
who fulfilled the 1987 classification criteria for RA [20],
were co-analysed with the registers of the Medical Biobank
cohorts. The study included 531 individuals (153 men and
378 women) referred to as pre-symptomatic individuals, all
of whom had donated at least one sample before the dis-
ease onset of RA, and 277 population-based controls (107
men and 170 women) randomly selected from the same
cohorts within the Medical Biobank. Ten samples from
identified pre-symptomatic individuals and five samples
from the controls were no longer available. Thus, 521
samples (from 150 men and 371 women) from the pre-
symptomatic individuals and 272 samples (from 105 men/
167 women) from the controls were analysed. The median
(IQR) time pre-dating the onset of symptoms of RA was
5.3 (6.0) years. A separate group of 241 patients (74 men
and 67 women) who had donated blood samples at the
time of RA diagnosis were included, all of whom had also
donated a sample pre-dating symptom onset. All of the in-
dividuals were classified as either being a “never-smoker”
or “ever a smoker” (including former or current smokers).
Descriptive data for the pre-symptomatic individuals, pa-
tients with RA and controls are presented in Table 1.
Radiographs of the hands and feet, available for 177
patients with RA at baseline and after 24 months, were
graded according to the Larsen score [21]. The smallest de-
tectable difference in the score was calculated to be 4 [22].
Antigenic peptides
Peptides used in this study were synthesized as multiple




CitHCitKVLCitDNIQGITKPAI)4K2KßA; and HCP2 (C
itH431-50):(KPAICitCitLACitCitGGVKCitISGLI) 4K2KßA.
Determination of anti-VCP and anti-HCP antibodies
Anti-VCP and anti-HCP antibodies were determined by
ELISA as previously described [14, 18, 19]. In each ELISA
a 7-point titration curve of a pool of ACPA+ RA plasma
with twofold dilution was included, setting the highest
concentration of the ACPA+ pool at 100 arbitrary units
(AU)/ml. Receiver operating characteristic (ROC) curves
were used to define the cutoff values for antibody positiv-
ity. The cutoff for anti-VCP1 IgG positivity was set at
32.89 AU/ml), anti-VCP2 IgG at 9.09 AU/ml, anti-HCP1
IgG at 19.51 AU/ml and anti-HCP2 IgG at 11.64 AU/ml,
corresponding to specificity of 98.2 %.
Analyses of anti-CCP2 antibodies and ACPA
Plasma were analysed using a microarray based on the
ImmunoCAP ISAC system (PhaDia) described previously
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for IgG ACPA specificity [8]. For this study only the three
antibodies with the highest frequencies analysed on the
same cohort of pre-symptomatic individuals as presented
in the previously mentioned study were selected; α-
enolase (CEP-1/Eno5-21, citrullinated at 9 and 15),
fibrinogenβ36-52 (Fibβ36-52, citrullinated at 44) and filag-
grin (CCP-1/Fil307-324, citrullinated at 312). The cutoff
values for ACPA were defined according to ROC-curve
analysis [8]. The presence of anti-citrullinated protein
antibodies (anti-CCP2), was also assessed with a cutoff of
25 AU/ml according to the manufacturer’s protocol (Euro
Diagnostica, Malmö, Sweden).
Genotyping
For the genotyping of HLA-DRB1, shared epitope (SE)
defined as HLA-DRB1*0401/0404/0405/0408/0101, poly-
merase chain reaction sequence-specific primers were
used, from a DR low-resolution kit and DRB1*04 and *01
subtyping kit (Dynal, Oslo, Norway) [23]. Data on gene
polymorphisms were extracted from Immunochip analysis
(SNP&SEQ Technology Platform Uppsala, Sweden) cover-
ing 314 single nucleotide polymorphisms (SNPs) for PADI
gene loci [24]. Information about the protein tyrosine
phosphatase, non-receptor type 22 (PTPN22) C1858T was
also extracted from the Immunochip analysis.
Statistics
Continuous data were compared using the Mann-
Whitney U test, and the Kruskal-Wallis test for more
than two groups. Categorical data were analysed using
the chi-square (X2) test or Fisher’s exact test, and Spear-
man’s rank correlation test (rs). The frequency distribution
was compared using Kendall’s-tau test. Logistic regression
analysis was used to identify associations between anti-
bodies and disease development and is presented as the
odds ratio (OR) with 95 % confidence interval (CI). Uni-
variate analysis of variance was used for analysing rela-
tionships between antibodies and continuous data. All of
the adjustments were based on the results from previously
performed studies, and p values ≤0.05 were considered
significant. All of the statistical analyses were performed
using SPSS 23.0 software (Chicago, IL, USA). Genetic ana-
lyses of SNPs in relation to concentration were performed
using PLINK (1.07) [25] with Bonferroni corrections and
Haploview (4.2), a program used for haplotype analysis
(http://www.broad.mit.edu/mpg/haploview).
Results
Concentrations of anti-VCP1, anti-VCP2, anti-HCP1 and
anti-HCP2 IgG in pre-symptomatic individuals, patients
with RA and controls
The concentrations of anti-VCP1, anti-VCP2, anti-HCP1
and anti-HCP2 IgG were all significantly increased in
the pre-symptomatic individuals and patients with RA
compared with controls (p < 0.001 for all eight analyses;
cases vs. controls) (Fig. 1a–d). The concentrations were
(mean ± SEM) 17.9 ± 1.5 AU/ml, 11.5 ± 1.4 AU/ml, 10.8 ±
1.2 AU/ml, and 11.3 ± 1.2 AU/ml in pre-symptomatic in-
dividuals, and 47.9 ± 4.2 AU/ml, 36.9 ± 3.7 AU/ml, 29.2 ±
3.0 AU/ml, and 38.0 ± 3.7 AU/ml in the patients with
RA, respectively, vs. 9.1 ± 0.5 AU/ml, 2.4 ± 0.14 AU/
ml, 4.4 ± 0.6 AU/ml, and 2.9 ± 0.3 AU/ml in the con-
trols. The concentrations of all four antibodies were
significantly increased in patients with RA compared
with the pre-symptomatic individuals both at a group
level and on an individual level (p < 0.001 for all analyses)
(Fig. 1a–d).
Frequency and combinations of positivity of anti-VCP1,
anti-VCP2, anti-HCP1 and anti-HCP2 IgG in pre-symptomatic
individuals and patients with RA in relation to controls
The frequency of the antibodies in pre-symptomatic indi-
viduals was highest (17.1 %) for anti-VCP2, followed by
anti-HCP2 at 16.3 %. The pattern was similar for the pa-
tients with RA with a frequency of 52.3 % for anti-VCP2
antibodies and 48.5 % for anti-HCP2 (Table 2). Overall,
samples from 147 pre-symptomatic individuals (28.2 %)
were positive for any of the antibodies, and the combin-
ation of anti-VCP1, anti-VCP2 and anti-HCP2 positivity
was most prevalent, being detected in samples from 27 in-
dividuals (18.4 %) (Fig. 2). The most frequent isolated
positive antibody was anti-HCP1 (15.6 %) (Fig. 2).
Table 1 Descriptive data for the pre-symptomatic individuals, patients with rheumatoid arthritis (RA) and the controls
Pre-symptomatic individuals (n = 521) Patients with RA (n = 241) Controls (n = 272)
Female sex, n (%) 371 (71.2) 167 (69.3) 167 (61.4)
Age, mean (SD)a, years 52.4 (9.4) 60.1 (9.7) 51.8 (9.5)
Ever-smoker, n (%) 327/520 (62.9) 162/240 (67.5) 110/266 (41.4)
HLA-SE carrierb, n (%) 249/392 (63.5) 147/218 (67.4) -
PTPN22 1858 T-variant carriage, n (%) 92/262 (35.1) 56/192 (29.2) -
Anti-CCP2 antibody, n (%) 190/518 (36.7) 189/241 (78.4) 7/272 (2.6)
aMean age (standard deviation) calculated for all pre-symptomatic individuals (n = 521) and patients with RA (n = 241). bHLA-DRB1 shared epitope (SE) defined
as 0101/0401/0404/0405/0408
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The OR for disease development in pre-symptomatic
individuals was higher for anti-VCP2 antibodies followed
by anti-HCP2 antibodies, (OR = 11.0, 95 % CI 4.4, 27.4
and OR = 10.4, 95 % CI 4.2, 26.0, respectively) (Table 2).
The combination of anti-VCP2+ and anti-HCP2+ anti-
bodies increased the OR for disease development to 17.2
(95 % CI 4.2, 71.1), and anti-VCP1+ HCP2+ antibodies to
18.9 (95 % CI 2.6, 139.0), respectively. The highest ORs
were achieved in combinations of anti-VCP1, anti-VCP2
and anti-HCP1, respectively, with anti-CCP2 antibodies
(OR = 25.2–25.8), in the pre-symptomatic individuals
(Table 2). The most frequent combination of all four anti-
bodies was anti-VCP1+, anti-VCP2+, anti-HCP1– and
anti-HCP2+, which yielded a high risk ratio (OR = 18.70,
95 % CI 2.53, 138.47) compared with negativity for all four
antibodies as reference (data not shown).
Positivity for three of the antibodies clearly increased
the OR for disease development, yielding an OR of 24.93
(95 % CI 3.40, 182.98), compared with those individuals
positive for only one of the antibodies, for whom the OR
was 6.23 (95 % CI 2.81, 13.83), being negative for all
antibodies as the reference (data not shown).
Fig. 1 a Concentrations of antibodies against viral citrullinated peptides derived from Epstein-Barr-virus derived protein (VCP1) in controls,
pre-symptomatic individuals and patients with rheumatoid arthritis (RA). Grey line indicates the mean of the concentrations; ***p < 0.001.
b Concentrations of anti-VCP2 antibodies in controls, pre-symptomatic individuals and patients with RA. Grey line indicates the mean of the
concentrations; ***p < 0.001. c Concentrations of antibodies against histone 4-derived citrullinated peptides (HCP1) in controls, pre-symptomatic
individuals and patients with RA. Grey line indicates the mean of the concentrations; ***p < 0.001. d Concentrations of anti-HCP2 antibodies in controls,
pre-symptomatic individuals and patients with RA. Grey line indicates the mean of the concentrations; ***p < 0.001. AU arbitrary units
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The anti-VCP1, anti-VCP2, anti-HCP1 and anti-HCP2
antibody concentrations and frequencies over time
The concentrations of anti-VCP1 anti-VCP2, anti-HCP1
and anti-HCP2 antibodies increased gradually over time
the closer to onset of symptoms the samples were col-
lected, (p < 0.001) (Fig. 3a). Also, the frequency of posi-
tivity increased the closer to onset of symptoms the
samples were collected for anti-VCP1, anti-VCP2 and
anti-HCP2 antibodies (p < 0.001 for all three) (Fig. 3b).
The number of positive antibodies increased the closer
to the onset of symptoms the samples were collected, in-
cluding all four antibodies (p < 0.001).
The time point of the first appearance of the individual
ACPA positivity did not differ significantly between the
four antibodies (anti-VCP1, anti-VCP2, anti-HCP1, anti-
HCP2), or anti-CEP-1, anti-Fibß36-52 or anti-filaggrin
antibodies. Positivity appeared first for anti-VCP2 anti-
bodies and the same sample was also positive for anti-
filaggrin antibodies (−17.5 years pre symptoms).
Antibody combinations with anti-CCP2 antibodies and
ACPA
Positivity for each of the four antibodies in the anti-
CCP2-positive individuals was almost the same in the
pre-symptomatic individuals as the total frequency of
positivity for each antibody (anti-VCP1, anti-VCP2, anti-
HCP1 and anti-HCP2 antibodies). Only up to 1.7 % of
any antibody was detected in anti-CCP2-negative indi-
viduals (Additional file 1). Positivity for the three most
frequent ACPA (anti-CEP-1, anti-Fibß36-52 and anti-
filaggrin antibodies) did not overlap with positivity to
the same extent for the four antibodies, anti-VCP1, anti-
VCP2, anti-HCP1 and anti-HCP2 (Additional files 2 and 3).
In particular, for anti-HCP1 the overlap in pre-symptom-
atic individuals, was less than 50 % (Additional file 2).
Comparison of the distribution of combinations of anti-
VCP1 and anti-VCP2 antibodies or anti-HCP1 and anti-
HCP2 antibodies, respectively, with anti-CCP2 antibodies
in pre-symptomatic individuals and after disease onset re-
vealed different patterns. The frequency of anti-CCP2
positivity increased after disease onset and the combina-
tions of anti-CCP2–, anti-VCP1–, anti-VCP2+ and anti-
CCP2–, anti-VCP1+, anti-VCP2+ antibodies disappeared
when comparing the pre-symptomatic individuals with pa-
tients with RA (Fig. 4a–b). The dominating changes of
combinations of anti-CCP2 antibodies with anti-VCP1 and
anti-VCP2 or anti-HCP1 and anti-HCP2 when the pre-
symptomatic individuals were compared with the patients
with RA were that the triple-negative groups (anti-
CCP2–, anti-VCP1–, anti-VCP2– or anti-CCP2–, anti-
HCP1–, anti-HCP2–, respectively) were reduced from
61.8 % to 21.2 % and 61.2 % to 19.9 %, respectively
(Fig. 4c–d). Of the individuals who were triple-
negative before the onset of symptoms, approximately
1/3 were still triple-negative after the onset of disease,
whilst almost 1/3 became triple-positive, concerning
both anti-HCP and anti-VCP antibodies. In all the cases
except for those remaining triple-negative the change was
Table 2 Frequency and odds ratio for anti-VCP1, anti-VCP2, anti-HCP1 and anti-HCP2 antibodies separately and in combinations, in
pre-symptomatic individuals and in patients with rheumatoid arthritis (RA) for disease development
Antibodies Antibody frequency in
pre-symptomatic individuals
(n = 521), % (95 % CI)
OR (95 % CI) Sensitivity in patients
with RA (n = 241),
% (95 % CI)
OR (95 % CI) Specificity,
% (95 % CI)
VCP1 10.4 (8, 13.3) 6.2 (2.4, 15.6) 36.1 (30.3, 42.3) 30.2 (12.0, 75.9) 98.2 (95.6, 99.3)
VCP2 17.1 (14.1, 20.6) 11.0 (4.4, 27.4) 52.3 (46, 58.5) 58.5 (23.3, 146.8) 98.2 (95.6, 99.3)
HCP1 10.2 (7.9, 13.1) 6.1 (2.4, 15.3) 37.3 (31.5, 43.6) 31.8 (12.7, 80.1) 98.2 (95.6, 99.3)
HCP2 16.3 (13.4, 19.8) 10.4 (4.2, 26.0) 48.5 (42.3, 54.8) 50.4 (20.1, 126.4) 98.2 (95.6, 99.3)
CCP2 36.7 (32.6, 40.9)a 21.9 (10.1, 47.4)a 78.4 (72.8, 83.1) 137.6 (61.2, 309.6) 97.4 (94.6, 98.8)
VCP1 + VCP2 8.6 (6.4, 11.2) 8.5 (2.6, 27.5) 32.8 (27.7, 39.0) 43.7 (13.6, 140.8) 98.9 (96.6, 99.8)
VCP1 + HCP1 1.5 (0.7, 3.1) - 17.0 (12.8, 22.3) 1.21 (1.1, 1.3) 100 (98.3, 100)
VCP1 + HCP2 6.5 (4.7, 9) 18.9 (2.6, 139.0) 28.6 (23.3, 34.7) 108.7 (15.0, 790.0) 99.6 (97.7, 100)
VCP2 + HCP1 3.1 (1.9, 5) - 25.7 (20.6, 31.6) 1.4 (1.3, 1.5) 100 (98.3, 100)
VCP2+ HCP2 11.3 (8.7, 14.2) 17.2 (4.2, 71.1) 40.2 (34.3, 46.6) 90.9 (22.1, 374.2) 99.3 (97.1, 100)
HCP1 + HCP2 5.6 (3.9, 7.9) 8.0 (1.9, 33.6) 26.6 (21.4, 32.5) 48.8 (11.8, 201.9) 99.3 (97.1, 100)
VCP1 + CCP2a 8.7 (6.6, 11.5) 25.8 (3.5, 188.1) 35.7 (29.9, 41.9) 150.4 (20.7, 1090.3) 99.6 (97.7, 100)
VCP2 + CCP2a 15.8 (12.8, 19.1) 25.2 (6.1, 103.2) 52.3 (46, 58.5) 147.9 (36.0, 608.2) 99.3 (97.1, 100)
HCP1 + CCP2a 8.3 (6.2, 11) 24.5 (3.4, 179.2) 35.7 (29.9, 41.9) 150.4 (20.7, 1090.3) 99.6 (97.7, 100)
HCP2 + CCP2a 15.4 (12.6, 18.9) 16.4 (5.1, 52.4) 48.5 (42.3, 54.8) 84.6 (26.4, 271.4) 98.9 (96.6, 99.0)
The antibodies are presented for the frequency of positivity, and with odds ratio (OR) and 95 % confidence interval (95 % CI). aFrequency in pre-symptomatic
individuals, n = 518. VCP, viral citrullinated peptides derived from Epstein-Barr-virus encoded protein; HCP, antibodies against histone 4-derived citrullinated
peptides, CCP cyclic citrullinated peptide
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created by anti-CCP2 antibodies becoming positive after
disease onset in all of the other combinations and thus,
moving the individuals to groups including anti-CCP2+.
The time pre-dating the onset of symptoms when the
samples were collected did not affect the distribution of
the combinations of positivity or negativity of the
antibodies.
Anti-VCP1, anti-VCP2, anti-HCP1, and anti-HCP2 IgG in
relation to risk factors for disease development and
radiological damage
HLA-DRB1-SE was associated with anti-VCP2 (p < 0.05),
and showed a trend for association with anti-HCP2 anti-
bodies (p = 0.057) in pre-symptomatic individuals. After
disease onset all four antibodies were associated with
HLA-SE, (p < 0.001–0.063). When analysing the contribu-
tion of individual SE alleles in pre-symptomatic individ-
uals, only DRB1*0401 was associated with positivity for
anti-VCP2 and for anti-HCP2 antibodies (p < 0.05 for
both). Pre-symptomatic individuals carrying the HLA-SE
and DRB1*0404 allele had significantly higher concentra-
tions of all four antibodies, but was significant only for
the DRB1*0404 allele and levels of anti-VCP2 antibodies
when adjusted for anti-CCP2 positivity. Individuals
with the DRB1*0401 allele had significantly higher levels
of anti-VCP1 and anti-VCP2 antibodies compared with
DRB1*0401-negative individuals (p < 0.001–0.014). The
combination of the DRB1*0404 and DRB1*0401 alleles did
not increase the risk of developing antibody positivity.
No significant association was found between the four
antibodies and age, sex, smoking or the PTPN22 T-
variant in pre-symptomatic individuals (data not shown).
In patients with RA being a smoker was only related to
the presence of anti-HCP2 antibodies (p < 0.05).
The SNPs (n = 314) from the Immunochip encoding
for PADI gene loci were analysed in relation to the con-
centrations of, or positivity for, the four antibodies. In the
pre-symptomatic individuals, the concentration of anti-
VCP1 antibodies was associated with 57 SNPs, which re-
duced to 21 when the levels were dichotomized (positive/
negative), whilst the other antibodies were only related to
a smaller number of the SNPs. None of these relationships
remained significant after correcting for multiple testing.
The patterns of association was fairly similar in the pa-
tients with RA, although with a higher number of asso-
ciations, and particularly between SNPs and antibody
Fig. 2 Combinations of positivity of the antibodies, anti-viral citrullinated peptides derived from Epstein-Barr-virus encoded protein (VCP1), anti-VCP2,
anti-histone 4-derived citrullinated peptides (HCP1) and anti-cyclic citrullinated peptide (CCP2) in pre-symptomatic individuals. Results are presented as
number and percentage of positive individuals, n (%)
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positivity for anti-HCP1 antibodies, where three of the as-
sociations remained significant after Bonferroni corrections
(rs3003444;imm_1_17485653; p < 2.17E-05, pcorr < 0.005,
rs7542629; imm_1_17495484; p < 0.0002, pcorr < 0.045,
rs11800688; imm_1_17504239; p < 6.88E-05, pcorr < 0.018).
Among the 314 SNPs of ImmunoChip, imm_1_17504969,
imm_1_17533086, imm_1_17535391 (corresponding to
rs1886303, PADI4_92, PADI4_96) or (rs11203366,
rs11203367 and rs874881) of the PADI4 haplotype de-
scribed by others were not associated with any of the
analysed antibodies, either as concentration or positivity,
(data not shown) [26-28].
These PADI3/PADI4 SNPs (rs3003444 G-variant,
rs7542629 and rs11800688 A-variants) were further ana-
lysed and found significantly associated with anti-HCP1
antibody positivity and concentration, independently of
adjustments for sex, age, HLA-SE and presence of anti-
CCP2 antibodies in patients with RA (Additional file 4).
Positivity for anti-HCP2 antibodies in patients with RA
was found to be associated with radiological evidence of
increased damage, as detected by higher Larsen scores
after 24 months, with a median (Q1-Q3) score of 10
(4–14) compared with a score of 8 (5–13) in anti-
HCP2-negative individuals (p < 0.05). This association
Fig. 3 a Mean concentration of the four antibodies during the period pre-dating the onset of symptoms up to the onset of rheumatoid arthritis
(RA), marked as 0. b Cumulative frequencies of the five antibodies during the period pre-dating the onset of symptoms up to the onset of RA,
marked as 0. VCP viral citrullinated peptide derived from Epstein-Barr-virus encoded protein, HCP histone 4-derived citrullinated peptides, CCP
cyclic citrullinated peptide
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remained after adjustment for the Larsen score at
baseline (p = 0.025), but not when adjusting for anti-
CCP2 antibodies. No differences could be found be-
tween radiological evidence of disease progression and
the three other antibodies, anti-VCP1, anti-VCP2 and
anti-HCP1 antibodies.
Discussion
We have recently demonstrated that citrullinated histone-
4 from activated neutrophils and viral citrullinated pep-
tides from Epstein-Barr virus nuclear proteins EBNA1 and
2 are targets for ACPA in sera from patients with RA [14,
18, 19]. In this study, we therefore took the opportunity to
investigate further the role of citrullinated-histone-4-de-
rived peptides and EBV-derived peptides in the aetiology
of RA, by analysing individuals before the onset of
symptoms of RA and by comparing the results with
those obtained with anti-CCP2 and citrullinated peptides
from alpha-enolase, fibrinogenß-chain and filaggrin.
Moreover, the association between anti-VCP and anti-
HCP antibodies and genes conferring predisposition
to RA was also investigated.
The concentrations of the antibodies against the HCP
and VCP antibodies were significantly increased in pre-
symptomatic individuals and patients with RA, compared
with control subjects. The highest frequency (17.1 %) was
found for anti-VCP2 followed by anti-HCP2 antibodies
(16.3 %) in pre-symptomatic individuals. The frequency in
patients with early RA was 52.3 % and 48.5 %, which is
consistent with previously published studies [13, 15], even
if the frequencies reported in those studies were slightly
higher, possibly because of the inclusion of patients with
an established disease. The majority of the individuals
positive for these four antibodies were also anti-CCP2-
positive. Thus, a small percentage of anti-VCP1- and anti-
VCP 2-positive and anti-HCP1- and anti-HCP 2-positive
individuals were not covered by anti-CCP2 positivity. This
evident overlap of anti-CCP2 antibodies with various
ACPA is in line with our previous publication [8]. On the
contrary, the anti-VCP and anti-HCP antibodies and the
three most frequent ACPA, namely antibodies against
CEP-1, Fibß36-52 and filaggrin only overlapped to a
minor extent, suggesting limited cross-reactivity and/or
independent production of these ACPAs.
Positivity for one single antibody confers a low risk of
development of RA, which increases when more antibody
specificities are present together. In fact, the combination
of anti-VCP2 and anti-HCP2 antibodies was found to
Fig. 4 a–d Clustering of anti-CCP2, anti-VCP1 and anti-VCP2, and anti-CCP2, anti-HCP1 and anti-HCP2 antibodies in individuals before onset of
rheumatoid arthritis (RA) symptoms and in patients with RA. VCP viral citrullinated peptide derived from Epstein-Barr-virus derived protein, HCP
histone 4-derived citrullinated peptides, CCP cyclic citrullinated peptide
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increase the OR to 17.2, but the highest ORs were for
anti-VCP1, anti-VCP2 and anti-HCP1, together with anti-
CCP2 antibodies. The OR for anti-CCP2 antibodies alone
was lower in the pre-symptomatic individuals (OR = 21.9).
In our previous study the OR was higher for the combin-
ation of two ACPA (e.g., anti-CEP1 and anti-Fib36-52
antibodies) (OR = 40.9, 95 % CI 19.8, 82.3), although the
number of analysed samples from pre-symptomatic indi-
viduals and controls were much higher, thus making com-
parisons on exact values difficult [8]. The major changes
that occurred in the distribution of the combinations of
anti-CCP2 and anti-VCP1 or anti-VCP2 or anti-HCP1 or
anti-HCP2 positivity comparing the pre-symptomatic in-
dividuals with the patients after diagnosis was that triple
antibody negativity converted to triple antibody positivity.
This conversion confirmed that both anti-HCP and anti-
VCP antibodies appear to play a potential role in the de-
velopment of RA, e.g., as they display a “classical” ACPA
pattern [8]. During the period pre-dating the onset of
symptoms the number of positive antibodies increased the
closer to onset of symptoms the samples were collected,
thus, suggesting an epitope spreading, as already reported
in other studies [8, 29]. From this study, we did not detect
any time difference in the appearance of positivity for any
of the antibodies against the citrullinated proteins from
histone H4 or from the EBV-derived proteins compared
with the other ACPA or anti-CCP2 antibodies. Thus,
examining the time course of antibody appearance, no
hierarchy among citrullinated epitopes of endogenous or
exogenous origin could be identified and no clues about a
single inciting antigen were obtained.
Examining the influence of genes conferring suscepti-
bility to RA, all four antibodies were found to be associ-
ated with HLA-SE after disease onset; on the contrary,
only anti-VCP2 antibodies were associated with HLA-
SE, even before symptom onset, as was already observed
with other ACPA specificities [30]. When analysing the
contribution of individual SE alleles in pre-symptomatic
individuals, the *0401 allele was associated with both
anti-VCP2 and anti-HCP2 antibody positivity, in line
with previous findings in a French Caucasian population
[31, 32]. Among the other genetic factors analysed, we
found no association between anti-VCP or anti-HCP
and PTPN22. However, three of the SNPs (rs3003444,
rs7542629 and rs11800688) in the PADI3/PADI4 inter-
genic region remained significantly associated with anti-
HCP1 antibodies after Bonferroni corrections and after
adjustments for e.g., anti-CCP2 antibodies, HLA-SE, age
and sex. These data suggest a relationship between PADI
polymorphisms and histone citrullination, a mechanism
hypothesised to be essential for the formation of NETs
and thereby the release of RA-associated autoantigens.
The SNP (rs3003444, A-allele) of PADI3/PADI4 has
been shown to be associated with disease development
in ACPA-positive patients with RA, who are of Chinese
origin [33], but no data are yet available in Caucasian
patients. The concentrations of anti-CCP2 and anti-
MCV antibodies have been associated with a haplotype
comprising three SNPs within the PADI4 gene [27, 28].
These SNPs were not associated with the antibodies
analysed in this study, including anti-CCP2 antibodies.
Irrespective of the potential inciting antigen of exogen-
ous or endogenous origin, ACPA specific for VCP and
HCP during the pre-symptomatic period follow the same
pattern (time of appearance and increase in concentra-
tions before onset). The present study suggests that
these antibodies have a potential role in the pathogenesis
of RA that could not be completely explained by, e.g., anti-
CEP-1, anti-Fibß36-52 or anti-filaggrin antibodies alone
and that certain combinations of the anti-VCP1, anti-
VCP2, anti-HCP1 and anti-HCP2 antibodies are associated
with an increased risk of developing RA. These results sug-
gest the need for investigating the relationship between
EBV infection and anti-VCP/ACPA production in longitu-
dinal studies involving patients pre RA. The described as-
sociation between the PADI3/PADI4 polymorphism and
anti-HCP1 antibodies suggests a novel link between deimi-
nation and production of ACPA. Our study has limitations:
the samples analysed were from different population sur-
veys, and were not collected on a regular basis. However,
we believe this to be the largest population-based study
performed to date analysing anti-VCP and anti-HCP anti-
body responses in individuals before onset of the symp-
toms of RA. Further studies are also needed to more
deeply investigate, in RA as well as in other autoimmune
disorders where NETosis is involved, the role of PADI3/
PADI4 SNPs in affecting enzyme levels and/or activity and
possibly histone deimination and NET formation.
Conclusions
Anti-VCP and anti-HCP antibodies pre-date symptom
onset and predict the development of RA, without hier-
archy among citrullinated epitopes. These results suggest
that no inciting citrullinated antigen is common to all
patients with RA. The association between the PADI3/
PADI4 polymorphism and anti-HCP1 antibodies sug-
gests a link between deimination and ACPA.
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